Literature DB >> 34145263

Immunological imprinting of the antibody response in COVID-19 patients.

Teresa Aydillo1,2, Alexander Rombauts3,4, Daniel Stadlbauer1, Sadaf Aslam1,2, Gabriela Abelenda-Alonso3,4, Alba Escalera1,2,5, Fatima Amanat1,5, Kaijun Jiang1, Florian Krammer6,7, Jordi Carratala8,9, Adolfo García-Sastre10,11,12,13.   

Abstract

In addition to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans are also susceptible to six other coronaviruses, for which consecutive exposures to antigenically related and divergent seasonal coronaviruses are frequent. Despite the prevalence of COVID-19 pandemic and ongoing research, the nature of the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Here we longitudinally profile the early humoral immune response against SARS-CoV-2 in hospitalized coronavirus disease 2019 (COVID-19) patients and quantify levels of pre-existing immunity to OC43, HKU1 and 229E seasonal coronaviruses, and find a strong back-boosting effect to conserved but not variable regions of OC43 and HKU1 betacoronaviruses spike protein. However, such antibody memory boost to human coronaviruses negatively correlates with the induction of IgG and IgM against SARS-CoV-2 spike and nucleocapsid protein. Our findings thus provide evidence of immunological imprinting by previous seasonal coronavirus infections that can potentially modulate the antibody profile to SARS-CoV-2 infection.

Entities:  

Year:  2021        PMID: 34145263     DOI: 10.1038/s41467-021-23977-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  48 in total

1.  Cross-protective immunity following coronavirus vaccination and coronavirus infection.

Authors:  Tanushree Dangi; Nicole Palacio; Sarah Sanchez; Mincheol Park; Jacob Class; Lavanya Visvabharathy; Thomas Ciucci; Igor J Koralnik; Justin M Richner; Pablo Penaloza-MacMaster
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

2.  Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.

Authors:  Muriel Aguilar-Bretones; Brenda M Westerhuis; Matthijs P Raadsen; Erwin de Bruin; Felicity D Chandler; Nisreen Ma Okba; Bart L Haagmans; Thomas Langerak; Henrik Endeman; Johannes Pc van den Akker; Diederik Ampj Gommers; Eric Cm van Gorp; Corine H GeurtsvanKessel; Rory D de Vries; Ron Am Fouchier; Barry Hg Rockx; Marion Pg Koopmans; Gijsbert P van Nierop
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

3.  Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors.

Authors:  Payton A-B Weidenbacher; Eric Waltari; Izumi de Los Rios Kobara; Benjamin N Bell; Mary Kate Morris; Ya-Chen Cheng; Carl Hanson; John E Pak; Peter S Kim
Journal:  Nat Chem Biol       Date:  2022-09-08       Impact factor: 16.174

4.  Antigenic imprinting in SARS-CoV-2.

Authors:  S Momsen Reincke; Harald Prüss; Ian A Wilson; Jakob Kreye
Journal:  Clin Transl Med       Date:  2022-07

5.  Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection.

Authors:  Jiong Wang; Bridget E Young; Dongmei Li; Antti Seppo; Qian Zhou; Alexander Wiltse; Anna Nowak-Wegrzyn; Katherine Murphy; Kaili Widrick; Nicole Diaz; Joseline Cruz-Vasquez; Kirsi M Järvinen; Martin S Zand
Journal:  Vaccines (Basel)       Date:  2022-06-20

Review 6.  Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations.

Authors:  Lily E Cohen; David J Spiro; Cecile Viboud
Journal:  PLoS Pathog       Date:  2022-06-30       Impact factor: 7.464

7.  Examination of Common Coronavirus Antibodies in SARS-CoV-2-Infected and Uninfected Participants in a Household Transmission Investigation.

Authors:  Megan M Stumpf; Brandi Freeman; Lisa Mills; Sandra Lester; Victoria T Chu; Hannah L Kirking; Natalie J Thornburg; Marie E Killerby
Journal:  Open Forum Infect Dis       Date:  2022-07-20       Impact factor: 4.423

8.  Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019.

Authors:  Priscila M S Castanha; Dylan J Tuttle; Georgios D Kitsios; Jana L Jacobs; Ulisses Braga-Neto; Matthew Duespohl; Sanjay Rathod; Michelle M Marti; Sarah Wheeler; Asma Naqvi; Brittany Staines; John Mellors; Alison Morris; Bryan J McVerry; Faraaz Shah; Caitlin Schaefer; Bernard J C Macatangay; Barbara Methe; Christian A Fernandez; Simon M Barratt-Boyes; Donald Burke; Ernesto T A Marques
Journal:  J Infect Dis       Date:  2022-09-13       Impact factor: 7.759

9.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

Authors:  Fatima Amanat; Mahima Thapa; Tinting Lei; Shaza M Sayed Ahmed; Daniel C Adelsberg; Juan Manuel Carreño; Shirin Strohmeier; Aaron J Schmitz; Sarah Zafar; Julian Q Zhou; Willemijn Rijnink; Hala Alshammary; Nicholas Borcherding; Ana Gonzalez Reiche; Komal Srivastava; Emilia Mia Sordillo; Harm van Bakel; Jackson S Turner; Goran Bajic; Viviana Simon; Ali H Ellebedy; Florian Krammer
Journal:  Cell       Date:  2021-06-08       Impact factor: 66.850

10.  Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice.

Authors:  Huibin Lv; Owen Tak-Yin Tsang; Ray T Y So; Yiquan Wang; Meng Yuan; Hejun Liu; Garrick K Yip; Qi Wen Teo; Yihan Lin; Weiwen Liang; Jinlin Wang; Wilson W Ng; Ian A Wilson; J S Malik Peiris; Nicholas C Wu; Chris K P Mok
Journal:  Eur J Immunol       Date:  2021-06-22       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.